1 |
F2
| [8] Phospholipase D signaling pathway Phospholipase D signaling pathway, Neuroactive ligand-receptor interaction, Complement and coagulation cascades, Platelet activation, Regulation of actin cytoskeleton, Pathogenic Escherichia coli infection, Coronavirus disease - COVID-19, Pathways in cancer | D09707
D09707
|
Dabigatran
| [4] 51 51, 85, 91, 124 |
2 |
ACHE
| [2] Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D00670
D00670
|
Donepezil
| [9] 5 5, 6, 13, 46, 78, 124, 127, 156, 206 |
3 |
ACHE
| [2] Glycerophospholipid metabolism Glycerophospholipid metabolism, Cholinergic synapse | D07869
D07869
|
Donepezil
| [9] 5 5, 6, 13, 46, 78, 124, 127, 156, 206 |
4 |
PDE3A
| [6] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Renin secretion, Morphine addiction | D01896
D01896
|
Cilostazol
| [3] 51 51, 70, 124 |
5 |
PDE3B
| [11] Purine metabolism Purine metabolism, Metabolic pathways, cGMP-PKG signaling pathway, cAMP signaling pathway, Apelin signaling pathway, Insulin signaling pathway, Progesterone-mediated oocyte maturation, Glucagon signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Morphine addiction | D01896
D01896
|
Cilostazol
| [3] 51 51, 70, 124 |
6 |
TBXA2R
| [3] Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Platelet activation | D01896
D01896
|
Cilostazol
| [3] 51 51, 70, 124 |
7 |
CALCA
| [2] Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Vascular smooth muscle contraction | D11055
D11055
|
Fremanezumab
| [2] 124 124, 226 |